Labcorp Perspectives: Oncology | Innovations in oncology: Highlights from ASCO's annual meeting (Episode 3)

The latest episode of Labcorp Perspectives: Oncology featuring Dr. Rebecca Previs, director of medical affairs at Labcorp Oncology, and Dr. Eric Severson, executive director of medical affairs at Labcorp, share notable insights from the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. They explore the role of liquid biopsies in cancer diagnostics, specifically Labcorp's Plasma Complete™ test, a noninvasive alternative to traditional biopsies.

Biomarkers of Immunotherapy Response: Current State-of-the-Art and Emerging Trends

Molecular Tumor Board: 56-year-old with endometrial cancer and POLE V411L alteration

Uterine cancer is the most common gynecologic cancer in the US, with increasing incidence and mortality rate. This Molecular Tumor Board case presented is about a 56-year-old female patient with uterine cancer and an underlying POLE V411L alteration. Join us as we discuss molecular subgroups in uterine cancer and how molecular classification impacts targeted therapy options.

ACMG 2024: From screening to diagnostic solutions: Comprehensive testing for women's health and wellness

Molecular Tumor Board: 52-year-old male with colon cancer and POLE P286R alteration

Did you know that a subset of patients with microsatellite-stable (MSS) colon cancer have POLE/POLD1 mutations that are associated with high clinical response to immunotherapy?

Join us for this molecular tumor board where we reviewed a case of metastatic MSS-colon cancer with a POLE mutation and high tumor mutational burden, detected on a comprehensive genomic and immune profiling (CGIP) platform. We discuss the incidence and therapeutic significance of POLE/POLD1 proofreading deficiency mutations in patients with colon cancer.

Labcorp Perspectives: Oncology | How can HRD testing help patients with ovarian cancer? (Episode 2)

Presented by:

Dr. Rebecca Previs, MD, Director of Medical Affairs at Labcorp

Dr. Alison Roos, PhD, Associate Director of Medical Affairs at Illumina

Molecular Tumor Board: 54-year-old male with accelerated phase CML and ABL1 T315I mutation

Molecular Tumor Board: 77-year-old female with metastatic breast cancer with PIK3CA H1047R mutation and 83-year-old female with metastatic breast cancer with AKT1 L52R mutation

Dr. Marcela Mazo Canola, Assistant Professor of Medicine, Breast Medical Oncology at UT Health San Antonio Mays Cancer Center joined our Oncology Medical Affairs Directors, Kyle Strickland and Heidi Ko to discuss the importance of biomarker testing for therapeutic implications in metastatic breast cancer. Two cases of metastatic hormone receptor-positive, HER2-negative breast cancer with PIK3CA and AKT1 alterations were discussed.

Labcorp Perspectives - Oncology: Understanding an inflamed tumor microenvironment and how to leverage it for targeted therapy(Episode 1)

Molecular Tumor Board: 58-year-old female with intrahepatic cholangiocarcinoma and FGFR2 fusion

In this Molecular Tumor Board, we review a case of intrahepatic cholangiocarcinoma with an FGFR2 fusion. We provide an overview of the different subtypes, risk factors, and prognosis of cholangiocarcinoma. We’ll also discuss recent developments of targeted therapies including FGFR inhibitors that have improved the outlook for patients with this cancer.